Did Orasure Technologies and These Stocks Miss or Beat Analyst Expectations?

OraSure Technologies Inc. (NASDAQ:OSUR) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share decreased to $-0.10 in the quarter versus EPS of $-0.07 in the year-earlier quarter. Revenue Rose 7.43% to $24.3 million from the year-earlier quarter.

OraSure Technologies Inc. reported adjusted EPS loss of $0.10 per share. By that measure, the company beat the mean analyst estimate of $-0.16. It beat the average revenue estimate of $23.67 million.

OSUR 20130811

DexCom, Inc. (NASDAQ:DXCM) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased to $-0.14 in the quarter versus EPS of $-0.21 in the year-earlier quarter. Revenue Rose 52.67% to $35.8 million from the year-earlier quarter.

DexCom, Inc. reported adjusted EPS loss of $0.14 per share. By that measure, the company beat the mean analyst estimate of $-0.16. It beat the average revenue estimate of $31.14 million.

DXCM 20130811

Array BioPharma, Inc. (NASDAQ:ARRY) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased to $-0.06 in the quarter versus EPS of $-0.09 in the year-earlier quarter. Revenue Rose 22.94% to $25.4 million from the year-earlier quarter.

Array BioPharma, Inc. reported adjusted EPS loss of $0.06 per share. By that measure, the company beat the mean analyst estimate of $-0.13. It beat the average revenue estimate of $16.13 million.

ARRY 20130811

Insulet Corporation (NASDAQ:PODD) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $-0.2 in the quarter versus EPS of $-0.30 in the year-earlier quarter. Revenue Rose 17.73% to $60.09 million from the year-earlier quarter.

Insulet Corporation reported adjusted EPS loss of $0.2 per share. By that measure, the company missed the mean analyst estimate of $-0.19. It missed the average revenue estimate of $60.47 million.

PODD 20130811

DepoMed Inc. (NASDAQ:DEPO) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased to $0.01 in the quarter versus EPS of $-0.28 in the year-earlier quarter. Revenue Rose 112.62% to $30 million from the year-earlier quarter.

DepoMed Inc. reported adjusted EPS income of $0.01 per share. By that measure, the company beat the mean analyst estimate of $-0.05. It beat the average revenue estimate of $29.87 million.

DEPO 20130811

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.